Lundbeck to acquire Longboard Pharmaceuticals for $2.5bn.

Lundbeck, a Danish international pharmaceutical company, agreed to acquire Longboard Pharmaceuticals, a clinical-stage biopharmaceutical company, for $2.5bn. “This transformative transaction will become a cornerstone in Lundbeck’s neuro-rare franchise, with a potential to drive growth into the next decade. Bexicaserin addresses a critical unmet need for patients suffering from rare and severe epilepsies, for which there are very few good treatment options available. With this acquisition, we continue to execute on our Focused Innovator strategy, transforming the lives of patients suffering from severe brain disorders," Charl van Zyl, Lundbeck President and CEO.